Review of NICE Technology Appraisal Guidance No 82; on the use oftacrolimus and pimecrolimus for the treatment of atopic eczema
Proposal to defer the review
The Institute has carried out a search for information relevant to this appraisal, and has found that to the best of its knowledge, no new evidence has been published that would have a material effect on the original guidance.
Consequently, we propose that the decision to review the original guidance be deferred until January 2009 when the evidence base will again be assessed to ascertain the need for a review of the guidance.
In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial. Please see Apppendix A for a full list of the organisations we have contacted.
Please note all comments received will be published on the Institute's website when a decision has been taken.
5 October 2007
This page was last updated: 23 December 2010